Kuros Biosciences Ltd.
19.99
EUR
+0.44
(+2.25%)
ISIN
CH0325814116
Return %
Stock
S&P 500
1Y
-40.86
14.20
3Y
1,111.52
81.12
5Y
1,111.52
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Christopher T. Fair
- Full Time Employees
- 178
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Wagistrasse 25 Schlieren ZH Switzerland 8952
- IPO Date
- Oct 29, 2002
- Website
- kurosbio.com
- Similar Companies
- Business
- Kuros Biosciences AG develops and commercializes innovative biologic technologies focused on bone repair and regeneration, specializing in advanced bone graft substitutes and orthobiologics. The company's core product portfolio centers around MagnetOs, an advanced synthetic bone graft platform that combines proprietary biomaterials and growth factors designed to promote predictable and enhanced bone healing in spinal, extremity, trauma, and oncology surgical applications. Product forms include MagnetOs Putty and MagnetOs Granules. Kuros serves global markets with commercial operations spanning more than 20 countries across five continents, including the United States, Europe, Australia, and the Middle East. The company also conducts extensive clinical trials to expand indications and evidence supporting its products, such as the ongoing ASTRA global clinical trial for foot and ankle fusion procedures. Founded in 2007 and headquartered in Schlieren (Zurich), Switzerland, Kuros operates subsidiaries in the United States and the Netherlands. Recent major developments include Kuros establishing a strategic exclusive sales agency agreement with Medtronic’s Spinal Division, advancing from a trial to a long-term alliance to enhance commercial scale and revenue growth through Medtronic’s distribution channels. This partnership underpins a significant increase in direct MagnetOs sales, which rose by 149% to CHF 50.6 million in the first nine months of 2024. Additionally, Kuros announced the enrollment of the first patient in the multinational ASTRA clinical study, reflecting the company’s expanded focus on extremities and foot and ankle surgery. Kuros has also broadened commercial clearances for MagnetOs Putty and Granules into new international markets including the UAE and Qatar and has onboarded new distributors in Australia and the UK for extremity and trauma applications. In 2023, Kuros expanded its manufacturing capacity by 50% through a CHF 10 million investment to meet forecasted market demand. The company is listed on the SIX Swiss Exchange under the ticker KURN.SW. Kuros Biosciences operates within the biotechnology and regenerative medicine industry, targeting orthopedic surgeons, trauma specialists, and healthcare providers requiring solutions for bone repair and fusion. Its business encompasses product development, regulatory approvals, clinical research, manufacturing, and global commercialization with a focus on innovative biomaterials for skeletal reconstruction and spinal fusion procedures.
Company News
Kuros Biosciences AG (CSBTF) Q2 2026 Earnings Call Transcript
Kuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
Kuros Biosciences AG (CSBTF) Q4 2025 Earnings Call Transcript